Market Intelligence, Pharmacogenomics, and High-Purity Reagents for Drug Metabolism Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for UGT1A7 drug discovery and ADMET profiling. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UGT1A7 Recombinant Protein (Wild-type & *3 Variant) – High purity (>95%), HEK293 Expressed, Sequence Verified. | View UGT1A7 Products |
| Gene Delivery | UGT1A7 ORF Clone / Lentivirus – Full-length ORF with native UGT1A7 sequence for stable cell line construction. | View UGT1A7 Products |
| Benchmark Ab | Anti-UGT1A7 Monoclonal Antibody – Recombinant positive control for Western Blot and ELISA validation. | View UGT1A7 Products |
| Validator | UGT1A7 siRNA Set (3 target-specific sequences) – For knockdown verification in hepatocyte models. | View UGT1A7 Products |
| Related Target: UGT1A1 | Major hepatic counterpart; competitive substrate analysis for selectivity profiling. | View UGT1A1 Products |
| Related Target: UGT1A9 | Overlapping substrate specificity with UGT1A7; essential for off-target liability assessment. | View UGT1A9 Products |
| Related Target: CYP3A4 | Phase I metabolism partner for synergistic DMPK profiling. | View CYP3A4 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Polymorphism Impact Assessment (*1/*2/*3 alleles) | Variant-specific recombinant proteins (WT, N129K, R131K) available with >95% purity; Sequence verified against NCBI RefSeq NM_014243. |
| Enzymatic Activity Standardization | HEK293 expressed proteins with native glycosylation; Endotoxin controlled (<1 EU/µg) to prevent macrophage activation bias. |
| Cross-Isoform Selectivity Screening | Homolog panel (UGT1A1/UGT1A6/UGT1A9) strictly verified by mass spec for substrate competition assays. |
| Subcellular Localization Studies | Lentivirus particles with ORF and IRES-GFP marker for ER retention verification in hepatocyte models. |
| Lack of Controls | Clinical Benchmark Antibodies included for precise assay calibration. |
| False Positives in cellular assays | Sequence-verified siRNA included for specificity checks and knockdown validation. |
Live UGT1A7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Pharmacogenomics Research
- ➤ Resistance & Detoxification Mechanisms
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The pharmaceutical industry's approach to UGT1A7 has shifted from basic enzymology to precision medicine applications. As a critical Phase II detoxification enzyme primarily expressed in extrahepatic tissues (gastrointestinal tract, lungs), UGT1A7 is responsible for glucuronidating SN-38 (the active metabolite of irinotecan) and various dietary carcinogens. The presence of functional single nucleotide polymorphisms (SNPs) in the UGT1A7 gene significantly impacts clearance rates and toxicity profiles of oncology drugs. Key mutations include N129K (rs17868323, c.387T>G) and R131K (rs386656364, c.622T>C) present in the *2 and *3 alleles, as well as rs17868324. Profiling UGT1A7 activity is now essential for ADMET screening and IND submissions. As personalized medicine advances, routine variant assessment is becoming a standard requirement for anticipating patient-specific drug-induced toxicities. Current development also focuses on selective UGT1A7 inhibitors to prevent drug detoxification in resistant tumors, with the field moving toward high-throughput enzymatic screening platforms requiring standardized, polymorphism-specific protein reagents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pharmacogenomic Testing | Roche, Thermo Fisher, Abbott | Irinotecan toxicity prediction; Colorectal cancer | Variant-specific Activity Assay (Need *1/*2/*3 recombinant proteins) |
| Small Molecule DMPK / Toxicology Screening | DMPK CROs | Pharmacokinetics, Drug-drug interaction | Enzyme Activity Assay (Need High-Purity Recombinant Proteins) |
| Selective Small Molecule Inhibitors | Academic Consortia | Multi-drug resistance reversal | Isoform Selectivity Panel (Need UGT1A1/UGT1A6/UGT1A9 cross-screening) |
| Companion Diagnostics | Qiagen, Myriad Genetics | Personalized oncology dosing | Positive Controls (Anti-UGT1A7 antibodies for IHC validation) |
| siRNA Therapeutics | Alnylam, Arrowhead | Hepatocyte-specific UGT inhibition | Knockdown Validation (Validated siRNA sets for efficacy confirmation) |